Peter E Auguste

List of Publications by Year
in descending order

20 papers	409 citations	840119 11 h-index	794141 19 g-index
20 all docs	20 docs citations	20 times ranked	831 citing authors

#	Article	IF	Citations
1	A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for glioblastoma multiforme. European Journal of Health Economics, 2021, 22, 89-100.	1.4	0
2	Cost-effectiveness of community health systems strengthening: quality improvement interventions at community level to realise maternal and child health gains in Kenya. BMJ Global Health, 2021, 6, e002452.	2.0	6
3	Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation. Health Technology Assessment, 2021, 25, 1-216.	1.3	3
4	Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2020, 38, 527-536.	1.7	8
5	Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent â€˜value for moneyâ€™ for the NHS? A rapid inquiry into suggestions that it may be cost-effective. Expert Opinion on Biological Therapy, 2020, 20, 823-827.	1.4	9
6	Conflicting findings between the Mitra-Fr and the Coapt trials: Implications regarding the cost-effectiveness of percutaneous repair for heart failure patients with severe secondary mitral regurgitation. PLoS ONE, 2020, 15, e0241361.	1.1	3
7	Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 19-27.	1.7	10
8	A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer. Clinical Drug Investigation, 2019, 39, 1153-1174.	1.1	7
9	Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model. Journal of Neuro-Oncology, 2019, 143, 605-611.	1.4	18
10	How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017. International Journal of Technology Assessment in Health Care, 2019, 35, 160-167.	0.2	17
11	Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages. BMC Neurology, 2018, 18, 162.	0.8	23
12	Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis. BMC Infectious Diseases, 2017, 17, 200.	1.3	106
13	Diabetic retinopathy and the use of laser photocoagulation: is it cost-effective to treat early?. BMJ Open Ophthalmology, 2017, 2, e000021.	0.8	10
14	Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohnâ€™s disease: a systematic review and meta-analysis. BMJ Open, 2017, 7, e014581.	0.8	13
15	Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technology Assessment, 2017, 21, 1-352.	1.3	24
16	A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying latent tuberculosis inÂ high-risk groups. Tuberculosis, 2016, 99, 81-91.	0.8	13
17	Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation. Health Technology Assessment, 2016, 20, 1-678.	1.3	30
18	Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-Î±) inhibitors [LISA-TRACKERÂ® enzyme-linked immunosorbent assay (ELISA) kits, TNF-Î±-Blocker ELISA kits and PromonitorÂ® ELISA kits] versus standard care in patients with Crohnâ€™s disease: systematic reviews and economic modelling. Health Technology Assessment, 2016, 20, 1-288.	1.3	27

#	Article	IF	Citations
19	Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-248.	1.3	53
20	Valuing the Health States Associated with Chlamydia trachomatis Infections and Their Sequelae: A Systematic Review of Economic Evaluations and Primary Studies. Value in Health, 2014, 17, 116-130.	0.1	29